Hematology/Oncology

Top Story

Ruxolitinib controls disease-related symptoms in CLL

Ruxolitinib controls disease-related symptoms in CLL
February 24, 2017

Ruxolitinib led to symptom improvement, including a reduction in fatigue, among patients with chronic lymphocytic leukemia who did not require systemic therapy, according to results of a prospective study.

“We have tried to address a very important and often neglected aspect of managing patients with CLL,” Preetesh Jain, MBBS, MD, DM, PhD, from the department of leukemia at The University of Texas MD Cancer Center, told HemOnc Today. “Adequate control of symptoms has not been a focus of clinical studies reported in patients with CLL.”

In the Journals

Immediate postmastectomy breast reconstruction may be a safe, effective option

February 24, 2017
In the postmastectomy radiation setting, immediate autologous breast reconstruction yielded similar complication and satisfaction rates as delayed reconstruction. The…
Meeting News

Researchers identify factors associated with survival in patients with blast phase CML

February 24, 2017
“Previously unknown” prognostic factors – including older age at diagnosis, high bone marrow blast percentage, higher LDH levels and previous tyrosine…
In the Journals

Mohs micrographic surgery comparable to wide local excision for melanoma in situ

February 24, 2017
There were no significant differences in outcomes for patients with melanoma in situ who were treated with Mohs micrographic surgery compared with those treated with…

AAFP, ACP, AAP among dozens urging House to keep all cigars under FDA authority

February 24, 2017
Citing statistics that show cigars are rising in popularity among youth, and the health threat they pose to people of all ages, more than 40 groups have jointly sent a…
More News Headlines »
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »
Video
Meeting News Coverage

VIDEO: Additional research necessary to define role of PARP inhibitors for BRCA–mutated breast cancer

January 9, 2017
More »
Featured
CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement